Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.sciencedirect.com/science?_ob=IssueURL&_tockey=%23TOC%235188%232003%23999789992%23376612%23FLA%23Volume_21,_Issues_7-8,_Pages_579-825_(30_January_2003)&_auth=y&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=bb6e1164294db947c398867fc34c89c9

Go to ScienceDirect Home Skip Main Navigation Links
 Register or Login:   Password:     Athens Login 
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile Help (Opens new window)
Issues
Vaccine
Copyright © 2003 Elsevier Science Ltd. All rights reserved

Volume 21, Issues 7-8,
Pages 579-825 (30 January 2003)
   
E-mail Articles
        Selected checked docs: display checked docs
1.
Preface, Page 579
Edouard Kurstak
Abstract | Full Text + Links | PDF (20 K)
2.
Towards the new global vaccinology era in prevention and control of diseases, Pages 580-581
Prof. Dr. Edouard Kurstak
Abstract | Full Text + Links | PDF (28 K)
3.
Bioterrorism and the biotechnologist, Pages 582-585
R. E. Spier
Abstract | Full Text + Links | PDF (42 K)
4.
New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund, Pages 587-592
Jacques-François Martin and John Marshall
Abstract | Full Text + Links | PDF (266 K)
5.
Vaccinology: past achievements, present roadblocks and future promises, Pages 593-595
Francis E. André
Abstract | Full Text + Links | PDF (40 K)
6.
The global value of vaccination, Pages 596-600
Jenifer Ehreth
Abstract | Full Text + Links | PDF (64 K)
7.
Recent progress in the development of vaccines for infants and children, Pages 601-604
E. David G. McIntosh and Peter R. Paradiso
Abstract | Full Text + Links | PDF (51 K)
8.
Two years into reverse vaccinology, Pages 605-610
Jeannette Adu-Bobie, Barbara Capecchi, Davide Serruto, Rino Rappuoli and Mariagrazia Pizza
Abstract | Full Text + Links | PDF (206 K)
9.
Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems, Pages 611-615
R. Glück and I. C. Metcalfe
Abstract | Full Text + Links | PDF (231 K)
10.
Prospects and challenges for prophylactic and therapeutic HIV vaccines, Pages 616-619
Michel Klein
Abstract | Full Text + Links | PDF (54 K)
11.
Therapeutic vaccination for future management of HIV/AIDS, Pages 620-623
Julianna Lisziewicz, Nyasha Bakare and Franco Lori
Abstract | Full Text + Links | PDF (55 K)
12.
V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential, Pages 624-628
Vichai Jirathitikal, Penpit Sooksathan, Orapun Metadilogkul and Aldar S. Bourinbaiar
Abstract | Full Text + Links | PDF (57 K)
13.
A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIVmac251 challenge in Rhesus Macaques, Pages 629-637
Karuppiah Muthumani, Mark Bagarazzi, Dan Conway, Daniel S. Hwang, Kelledy Manson, Richard Ciccarelli, Zimmra Israel, David C. Montefiori, Kenneth Ugen, Nancy Miller et al.
Abstract | Full Text + Links | PDF (172 K)
14.
Virus-like particle and DNA-based candidate AIDS vaccines, Pages 638-643
Qizhi Yao, Zhigao Bu, Andrei Vzorov, Chinglai Yang and Richard W. Compans
Abstract | Full Text + Links | PDF (185 K)
15.
Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella, Pages 644-648
Fengfeng Xu, Mei Hong and Jeffrey B. Ulmer
Abstract | Full Text + Links | PDF (63 K)
16.
Induction of immune responses by DNA vaccines in large animals, Pages 649-658
L. A. Babiuk, R. Pontarollo, S. Babiuk, B. Loehr and S. van Drunen Littel-van den Hurk
Abstract | Full Text + Links | PDF (159 K)
17.
Progress in DNA vaccine for prophylaxis and therapy of hepatitis B, Pages 659-662
Alexandre Thermet, Christine Rollier, Fabien Zoulim, Christian Trepo and Lucyna Cova
Abstract | Full Text + Links | PDF (71 K)
18.
The rationale of a peptide-conjugate vaccine against measles, Pages 663-666
Mike M. Pütz and Claude P. Muller
Abstract | Full Text + Links | PDF (47 K)
19.
Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments, Pages 667-670
Guido Dietrich, Jean-Francois Viret and Jürgen Hess
Abstract | Full Text + Links | PDF (57 K)
20.
Development of surrogate markers for oral immunisation against Candida albicans, Pages 671-677
Shokrollah Elahi, Gerald Pang and Robert Clancy
Abstract | Full Text + Links | PDF (235 K)
21.
Experience with registered mucosal vaccines, Pages 678-683
Guido Dietrich, Monika Griot-Wenk, Ian C. Metcalfe, Alois B. Lang and Jean-François Viret
Abstract | Full Text + Links | PDF (101 K)
22.
Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy, Pages 685-691
Paolo Bonanni, Giovanna Pesavento, Angela Bechini, Emilia Tiscione, Francesco Mannelli, Cristiana Benucci and Antonella Lo Nostro
Abstract | Full Text + Links | PDF (192 K)
23.
Primary prevention of hepatitis C virus infection, Pages 692-695
Alessandro R. Zanetti, Luisa Romanò andSilvia Bianchi
Abstract | Full Text + Links | PDF (46 K)
24.
Vaccination strategies against hepatitis A in southern Europe, Pages 696-697
Elisabetta Franco and Giuseppe Vitiello
Abstract | Full Text + Links | PDF (34 K)
25.
Effectiveness of a mass hepatitis A vaccination program in preadolescents, Pages 698-701
Àngela Domínguez, Lluís Salleras, Glòria Carmona and Juan Batalla
Abstract | Full Text + Links | PDF (51 K)
26.
Costs and benefits of polio eradication: a long-run global perspective, Pages 702-705
M. Mahmud Khan and Jennifer Ehreth
Abstract | Full Text + Links | PDF (48 K)
27.
The challenge to provide affordable rabies post-exposure treatment, Pages 706-709
Mary J. Warrell
Abstract | Full Text + Links | PDF (76 K)
28.
Human rabies prophylactics: the French experience, Pages 710-715
Y. Rotivel, M. Goudal and A. Simons de Fanti
Abstract | Full Text + Links | PDF (226 K)
29.
Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b, Pages 716-720
H. E. de Melker, S. van den Hof, G. A. M. Berbers and M. A. E. Conyn-van Spaendonck
Abstract | Full Text + Links | PDF (157 K)
30.
Options for improvement of the Dutch measles vaccination schedule, Pages 721-724
S. van den Hof, J. Wallinga, M. -A. Widdowson and M. A. E. Conyn-van Spaendonck
Abstract | Full Text + Links | PDF (49 K)
31.
Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain, Pages 725-728
L. Salleras, A. Domínguez and N. Cardeñosa
Abstract | Full Text + Links | PDF (205 K)
32.
Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine, Pages 729-733
L. Salleras, A. Domínguez and N. Cardeñosa
Abstract | Full Text + Links | PDF (299 K)
33.
Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease, Pages 734-737
J. Holst, B. Feiring, J. E. Fuglesang, E. A. Høiby, H. Nøkleby, I. S. Aaberge and E. Rosenqvist
Abstract | Full Text + Links | PDF (66 K)
34.
Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults, Pages 738-741
Olaf Zent, Jiri Beran, Wolfgang Jilg, Tomasz Mach and Angelika Banzhoff
Abstract | Full Text + Links | PDF (56 K)
35.
Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN "NEW" in children: results of post-marketing surveillance, Pages 742-745
Borislava G. Pavlova, Alexandra Loew-Baselli, Sandor Fritsch, Eva-Maria Poellabauer, Nina Vartian, Ingeborg Rinke and Hartmut J. Ehrlich
Abstract | Full Text + Links | PDF (48 K)
36.
Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing protective listerial epitopes within a surface-exposed loop of the TolC-protein, Pages 746-752
Simone Spreng, Guido Dietrich, Werner Goebel and Ivaylo Gentschev
Abstract | Full Text + Links | PDF (211 K)
37.
Priming characteristics of peptide mimotopes of carbohydrate antigens, Pages 753-760
Behjatolah Monzavi-Karbassi, Shahram Shamloo, Matthew Kieber-Emmons, Fariba Jousheghany, Ping Luo, Kaity Y. Lin, Gina Cunto-Amesty, David B. Weiner and Thomas Kieber-Emmons
Abstract | Full Text + Links | PDF (241 K)
38.
Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes, Pages 761-767
Anthony H. -C. Choi, Monica M. McNeal, Mitali Basu, Judy A. Bean, John L. VanCott, John D. Clements and Richard L. Ward
Abstract | Full Text + Links | PDF (105 K)
39.
Transcriptome-based antigen identification for Neisseria meningitidis, Pages 768-775
Sebastian Kurz, Claudia Hübner, Christian Aepinus, Stephanie Theiss, Matthias Guckenberger, Ursula Panzner, Jacqueline Weber, Matthias Frosch and Guido Dietrich
Abstract | Full Text + Links | PDF (137 K)
40.
Immunity under the skin: potential application for topical delivery of vaccines, Pages 776-780
C. D. Partidos, A. -S. Beignon, F. Mawas, G. Belliard, J. -P. Briand and S. Muller
Abstract | Full Text + Links | PDF (102 K)
41.
Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects, Pages 781-786
Michael Kalos
Abstract | Full Text + Links | PDF (64 K)
42.
Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®), Pages 787-790
M. Adams, H. Navabi, B. Jasani, S. Man, A. Fiander, A. S. Evans, C. Donninger and M. Mason
Abstract | Full Text + Links | PDF (54 K)
43.
Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia, Pages 791-794
M. Grégoire, C. Ligeza-Poisson, N. Juge-Morineau and R. Spisek
Abstract | Full Text + Links | PDF (166 K)
44.
Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine, Pages 795-797
David Berd
Abstract | Full Text + Links | PDF (54 K)
45.
Towards new immunotherapies: targeting recombinant cytokines to the immune system using live attenuated Salmonella, Pages 798-801
Claudia D. Rosenkranz, Damasia Chiara, Caroline Agorio, Adriana Baz, Marcela F. Pasetti, Fernanda Schreiber, Silvia Dematteis, Miguel Martinez, Marcelo B. Sztein and Jose A. Chabalgoity
Abstract | Full Text + Links | PDF (54 K)
46.
Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives, Pages 803-808
Francesco Sala, M. Manuela Rigano, Alessandra Barbante, Barbara Basso, Amanda M. Walmsley and Stefano Castiglione
Abstract | Full Text + Links | PDF (66 K)
47.
Targeting of plant-derived vaccine antigens to immunoresponsive mucosal sites, Pages 809-811
M. Manuela Rigano, Francesco Sala, Charles J. Arntzen and Amanda M. Walmsley
Abstract | Full Text + Links | PDF (46 K)
48.
Corn as a production system for human and animal vaccines, Pages 812-815
Stephen J. Streatfield, Jeffrey R. Lane, Christopher A. Brooks, Donna K. Barker, Miranda L. Poage, Jocelyne M. Mayor, Barry J. Lamphear, Carol F. Drees, Joseph M. Jilka, Elizabeth E. Hood and John A. Howard
Abstract | Full Text + Links | PDF (116 K)
49.
Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults, Pages 816-819
Claude P. Muller, Fred Fack, Benjamin Damien and Fabienne B. Bouche
Abstract | Full Text + Links | PDF (64 K)
50.
Production of antibodies in plants and their use for global health, Pages 820-825
Rainer Fischer, Richard M. Twyman and Stefan Schillberg
Abstract | Full Text + Links | PDF (111 K)
51.
Fourth World Congress on Vaccines and Immunisation, September 29–October 3 2004, Tsukuba Science City, Japan, Page I

PDF (21 K)
52.
Editorial Board/Aims and Scope, Page CO2

PDF (42 K)


 

E-mail Articles
Issues
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile   Help (Opens new window)


 

Send feedback to ScienceDirect
Software and compilation © 2003 ScienceDirect. All rights reserved.
ScienceDirect® is an Elsevier Science B.V. registered trademark.


Your use of this service is governed by Terms and Conditions. Please review our Privacy Policy for details on how we protect information that you supply.

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.